Bristol-Myers Squibb: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 6Phase 2 9Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT03743246Phase 1/2Results posted
• Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02535364Phase 2Results posted
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseCompletedNCT02369653Phase 3Results posted
• Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01460160Phase 2Results posted
• Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CMLCompletedNCT00123487Phase 3Results posted
• A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02973191Phase 1/2
• Long-Term Follow-up Study for Patients Previously Treated With JCAR015CompletedNCT02813252
• Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT01363817Phase 1
• Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWithdrawnNCT00349518Phase 2/3
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCompletedNCT00298987Phase 2
• BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2